In a recent interview, Dr. Alberto Montero, a medical oncologist at Case Western Reserve University, highlighted two key points that every woman should know about breast cancer: early detection saves lives, and most cases are not caused by inherited gene mutations.
Survival Rates Have Leaped Since the 1970s
Dr. Montero noted that five‑year survival for breast cancer patients was in the 70% range in the 1970s. Today, thanks to advances in screening and treatment, survival is upwards of 95% for many women. The National Cancer Institute’s SEER program reports a five‑year relative survival of 91.9% for women diagnosed between 2016 and 2022, compared with roughly 76% for those diagnosed in the mid‑1970s.
When cancer is caught while still confined to the breast—about 64% of cases—the five‑year relative survival reaches 100%, meaning those patients are as likely to be alive five years later as women who never had the disease.
Mammography Remains the Gold Standard
According to Dr. Montero, mammography continues to be the benchmark against which all other screening methods are measured. Current guidelines recommend a baseline mammogram around age 40 for women at average risk. Women with a strong family history or a known genetic mutation follow a different screening algorithm, and their physicians can tailor a plan based on individual risk.
Genetics Play a Small Role
“Ninety percent of women who develop breast cancer do not have a genetic cause,” Dr. Montero emphasized. Inherited gene mutations, such as BRCA1 and BRCA2, account for only about 5% to 10% of breast cancers. While a harmful BRCA mutation raises a woman’s lifetime risk to more than 60%, the general population risk remains around 13%.
The American Society of Clinical Oncology and the Society of Surgical Oncology now recommend offering BRCA testing to every patient diagnosed at age 65 or younger, and to selected older patients based on family history, ancestry, tumor type, or eligibility for specific therapies.
Molecular Testing Guides Treatment Decisions
Advances in molecular testing have also transformed how doctors decide on chemotherapy. The TAILORx trial, which enrolled 10,273 women with hormone‑receptor‑positive, HER2‑negative, node‑negative breast cancer, used a 21‑gene assay to stratify risk. The study found that 69% of participants fell into an intermediate risk group for whom hormone therapy alone was as effective as hormone therapy plus chemotherapy, especially for women over 50.
Dr. Montero explained that this shift allows physicians to personalize treatment, sparing many patients from unnecessary chemotherapy and its associated toxicities.
Four Main Subtypes Inform Care
Research now recognizes at least four breast‑cancer subtypes—luminal A, luminal B, HER2‑enriched, and basal‑like (which overlaps with triple‑negative breast cancer). While treatment decisions are primarily driven by stage, grade, hormone‑receptor status, and HER2 status, these molecular categories help clinicians understand each tumor’s natural history.
Overall, the combination of early detection, refined screening guidelines, and precise molecular testing has turned breast cancer into a highly treatable disease for the vast majority of women.
What Women Should Take Away
Women should schedule a baseline mammogram around age 40, discuss personal and family risk factors with their physicians, and stay informed about genetic testing options if they have a strong family history. By catching cancer early and leveraging modern testing, patients can avoid overtreatment and achieve excellent outcomes.
Original reporting: KEYT (Ventura/Santa Barbara) — read the source article.
